Michigan Cancer Research Consortium

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study

Plain Language SummaryWhat is this summary about?This summary describes how well talquetamab worked and its safety at a median (midpoint) of 17–26 months follow-up from the MonumenTAL-1 study, which tested talquetamab treatment for a type of cancer called relapsed/refractory mult...

Lasting Financial and Professional Impacts Among Survivors of Early-Onset Colorectal Cancer

BACKGROUND: Patients with early-onset colorectal cancer (age < 50) are vulnerable to unique psychosocial consequences given their developmental stage in life. Younger adults are often establishing their careers and families, and a cancer diagnosis can contribute to financial and...